News | November 06, 2024
Venus Remedies gets approval from Malaysian PIC/S GMP for pre-filled syringe facility
The recognition from Malaysia's NPRA, a member of PIC/S, opens doors to new global business opportunities
The recognition from Malaysia's NPRA, a member of PIC/S, opens doors to new global business opportunities
Raises 2024 revenue guidance to a range of US$ 61 to US$ 64 billion
Commercial license to Synaffix technologies follows a series of successful initial preclinical proof of concept studies
He has 35+ years of experience in understanding of business and products, analytical ability, eye for detail and computer literacy and knowledge of recent trends.
Partnership to Combine AbbVie's Oncology Expertise with EvolveImmune's Proprietary EVOLVE T-Cell Engager Platform to Develop Novel Multispecific Therapeutic Antibodies for Cancer
The newly setup entity, Emcutix Biopharmaceuticals Limited, plans to significantly expand Emcure’s offerings
Revenue at Rs 3,623 crore, EBITDA at Rs 718 crore
Reinforces position as first commercially approved contract development and manufacturing organization (CDMO) for ADCs in North America
The partnership emphasises the introduction of renewable, bio-based materials into existing plastic applications to help reduce fossil resource dependency
Lupin's R&D teams are working on products with a near-zero global warming potential propellant
Subscribe To Our Newsletter & Stay Updated
